Grant: CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship
University of Calgary
$67,500.00
Allogeneic CD3+ CD4- CD8- double-negative T cell as a novel treatment for AML patients relapsed after allo-HSCT.
EF 2024-25
Résumé
Background: Acute myeloid leukemia (AML) remains a significant clinical challenge, with disease relapse following allogeneic
hematopoietic stem cell transplantation (allo-HSCT) as the leading cause of mortality. While donor-derived conventional T (Tconv)
cells mediate the graft-versus-leukemia (GvL) effect, they also contribute to graft-versus-host disease (GvHD), which significantly
impacts patient survival and quality of life. Addressing the challenge of enhancing GvL without exacerbating GvHD is crucial to
improving allo-HSCT outcomes.
Double-negative T cells (DNTs) are a unique subset of mature T cells that lack CD4, CD8, and natural killer T (NKT) cell markers. We
have demonstrated that ex vivo-expanded, healthy donor-derived DNTs effectively target AML cells without inducing GvHD. Our
phase I clinical trial in patients who relapsed post-allo-HSCT showed that DNT therapy is feasible, safe, and potentially efficacious,
with a 2-year overall survival rate of 50%, compared to 21.1% in historical controls. Importantly, our recent findings indicate that
DNTs enhance CD8+ T cell cytotoxicity against AML while simultaneously suppressing GvHD, suggesting their potential as an
adjuvant therapy to allo-HSCT.
Objective and Hypothesis: This study aims to investigate how DNTs synergize with CD8+ T cells to exert MHC-independent antileukemic
effects while mitigating GvHD. We hypothesize that DNT-activated CD8+ T cells selectively eliminate AML cells by
engaging stress receptors (e.g., DNAM-1) and inducing ferroptosis, an iron-dependent form of cell death to which AML cells are
particularly vulnerable. By elucidating the interplay between DNTs and Tconv cells, we aim to establish DNT-based adjuvant
therapies capable of preventing leukemic relapse and GvHD in allo-HSCT recipients.
Specific Aims:
Aim 1: Elucidate how CD8+ T cells activated by DNTs selectively target AML cells. Our preliminary data suggest that DNT-activated
CD8+ T cells exhibit robust, MHC-independent, DNAM-1-dependent cytotoxicity against AML. To validate these findings, we will
assess the contribution of DNAM-1 and other stress receptors in vitro using additional AML cell lines and primary AML blasts. We will
further evaluate these mechanisms in vivo using AML xenograft models in ß2m KO NSG mice, minimizing alloreactivity. Additionally,
we will perform single-cell RNA sequencing to identify novel molecules involved in DNT-activated CD8+ T cell cytotoxicity against
AML.
Aim 2: Dissect the role of ferroptosis in DNT-activated CD8+ T cell function. Our proteomics analysis revealed ferroptosis as a key
pathway enriched in DNT-activated CD8+ T cells. To investigate the importance of ferroptosis, we will evaluate the effect of
ferroptosis inhibitors on CD8+ T cell-mediated AML killing in vitro and in AML xenograft models. Additionally, we will assess the role
of cytokines, such as IFN? and TNFa, in promoting ferroptosis using transwell assays and cytokine blockade experiments. These
studies will provide mechanistic insights into the unconventional cytotoxic pathways driven by DNT-activated CD8+ T cells.
Impact and Significance: This study addresses the urgent need to enhance GvL responses while mitigating GvHD in allo-HSCT
recipients. Our findings will provide a mechanistic foundation for optimizing DNT-based immunotherapies, potentially reducing
leukemia relapse and improving post-transplant outcomes. Furthermore, by establishing ferroptosis as a key effector mechanism,
this research can change our understanding of the interaction between T cells and AML cells and how we can decipher GvL effect
from GvHD.
Programme
CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537936
Name
Lee Jong Bok
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Allogeneic CD3+ CD4- CD8- double-negative T cell as a novel treatment for AML patients relapsed after allo-HSCT.
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship
Keyworddelim
Cancer
Abstract
Background: Acute myeloid leukemia (AML) remains a significant clinical challenge, with disease relapse following allogeneic
hematopoietic stem cell transplantation (allo-HSCT) as the leading cause of mortality. While donor-derived conventional T (Tconv)
cells mediate the graft-versus-leukemia (GvL) effect, they also contribute to graft-versus-host disease (GvHD), which significantly
impacts patient survival and quality of life. Addressing the challenge of enhancing GvL without exacerbating GvHD is crucial to
improving allo-HSCT outcomes.
Double-negative T cells (DNTs) are a unique subset of mature T cells that lack CD4, CD8, and natural killer T (NKT) cell markers. We
have demonstrated that ex vivo-expanded, healthy donor-derived DNTs effectively target AML cells without inducing GvHD. Our
phase I clinical trial in patients who relapsed post-allo-HSCT showed that DNT therapy is feasible, safe, and potentially efficacious,
with a 2-year overall survival rate of 50%, compared to 21.1% in historical controls. Importantly, our recent findings indicate that
DNTs enhance CD8+ T cell cytotoxicity against AML while simultaneously suppressing GvHD, suggesting their potential as an
adjuvant therapy to allo-HSCT.
Objective and Hypothesis: This study aims to investigate how DNTs synergize with CD8+ T cells to exert MHC-independent antileukemic
effects while mitigating GvHD. We hypothesize that DNT-activated CD8+ T cells selectively eliminate AML cells by
engaging stress receptors (e.g., DNAM-1) and inducing ferroptosis, an iron-dependent form of cell death to which AML cells are
particularly vulnerable. By elucidating the interplay between DNTs and Tconv cells, we aim to establish DNT-based adjuvant
therapies capable of preventing leukemic relapse and GvHD in allo-HSCT recipients.
Specific Aims:
Aim 1: Elucidate how CD8+ T cells activated by DNTs selectively target AML cells. Our preliminary data suggest that DNT-activated
CD8+ T cells exhibit robust, MHC-independent, DNAM-1-dependent cytotoxicity against AML. To validate these findings, we will
assess the contribution of DNAM-1 and other stress receptors in vitro using additional AML cell lines and primary AML blasts. We will
further evaluate these mechanisms in vivo using AML xenograft models in ß2m KO NSG mice, minimizing alloreactivity. Additionally,
we will perform single-cell RNA sequencing to identify novel molecules involved in DNT-activated CD8+ T cell cytotoxicity against
AML.
Aim 2: Dissect the role of ferroptosis in DNT-activated CD8+ T cell function. Our proteomics analysis revealed ferroptosis as a key
pathway enriched in DNT-activated CD8+ T cells. To investigate the importance of ferroptosis, we will evaluate the effect of
ferroptosis inhibitors on CD8+ T cell-mediated AML killing in vitro and in AML xenograft models. Additionally, we will assess the role
of cytokines, such as IFN? and TNFa, in promoting ferroptosis using transwell assays and cytokine blockade experiments. These
studies will provide mechanistic insights into the unconventional cytotoxic pathways driven by DNT-activated CD8+ T cells.
Impact and Significance: This study addresses the urgent need to enhance GvL responses while mitigating GvHD in allo-HSCT
recipients. Our findings will provide a mechanistic foundation for optimizing DNT-based immunotherapies, potentially reducing
leukemia relapse and improving post-transplant outcomes. Furthermore, by establishing ferroptosis as a key effector mechanism,
this research can change our understanding of the interaction between T cells and AML cells and how we can decipher GvL effect
from GvHD.
Competitiondate
202502
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lee, Jong Bok
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $67,500~ $0~